MERS
MCID: MDD018
MIFTS: 43

Middle East Respiratory Syndrome (MERS)

Categories: Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Middle East Respiratory Syndrome

MalaCards integrated aliases for Middle East Respiratory Syndrome:

Name: Middle East Respiratory Syndrome 12 58 15
Mers 58

Classifications:



External Ids:

Disease Ontology 12 DOID:0080642
Orphanet 58 ORPHA576074

Summaries for Middle East Respiratory Syndrome

Disease Ontology : 12 A Coronavirus infection that is characterized by severe respiratory illness, including fever, cough, and shortness of breath and that has material basis in MERS-CoV.

MalaCards based summary : Middle East Respiratory Syndrome, also known as mers, is related to viral pneumonia and avian influenza. An important gene associated with Middle East Respiratory Syndrome is DPP4 (Dipeptidyl Peptidase 4), and among its related pathways/superpathways are NF-kappaB Signaling and Cytosolic sensors of pathogen-associated DNA. The drugs Dexmedetomidine and Heparin have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and brain, and related phenotype is respiratory system.

Wikipedia : 74 Middle East respiratory syndrome (MERS), also known as camel flu, is a viral respiratory infection... more...

Related Diseases for Middle East Respiratory Syndrome

Diseases related to Middle East Respiratory Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 269, show less)
# Related Disease Score Top Affiliating Genes
1 viral pneumonia 30.7 IFNB1 CXCL10 ACE2
2 avian influenza 30.7 ISG15 FURIN CXCL10
3 ebola hemorrhagic fever 30.7 SCARA3 IFNB1 FURIN
4 vaccinia 30.5 ISG15 IRF3 IFNB1 CEACAM5
5 severe acute respiratory syndrome 30.5 TMPRSS2 IRF3 IFNB1 IFIH1 FURIN CXCL10
6 encephalitis 30.5 PPP1CA IRF3 IFNB1 CXCL10
7 covid-19 30.4 TMPRSS2 FURIN DPP4 CTSL ACE2
8 lassa fever 30.1 SCARA3 IRF3 IFIH1
9 newcastle disease 30.1 IRF3 IFNB1 CXCL10
10 venezuelan equine encephalitis 29.8 PPP1CA IFNB1 CXCL10
11 human immunodeficiency virus type 1 29.7 IRF3 HSPA5 DPP4 CXCL10 ADA
12 influenza 29.6 TMPRSS2 ISG15 IRF3 IFNB1 IFIH1 FURIN
13 immune deficiency disease 29.5 IFNB1 FURIN CXCL10 ADA
14 coronavirus infectious disease 27.8 TMPRSS2 SCARA3 PPP1CA ISG15 IRF3 IFNB1
15 encephalitis/encephalopathy, mild, with reversible myelin vacuolization 11.7
16 respiratory failure 10.5
17 encephalopathy 10.5
18 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
19 diarrhea 10.4
20 pneumonia 10.4
21 listeria meningitis 10.4 IFNB1 ADA
22 squamous cell bile duct carcinoma 10.4 DPP4 CEACAM5
23 leukemia, acute lymphoblastic 10.4
24 adult dermatomyositis 10.3 ISG15 IFIH1
25 vulva basal cell carcinoma 10.3 CTSL CEACAM5
26 sting-associated vasculopathy with onset in infancy 10.3 IRF3 IFNB1 IFIH1
27 cutaneous anthrax 10.3 FURIN ADA
28 crimean-congo hemorrhagic fever 10.3 IFNB1 FURIN CXCL10
29 herpangina 10.3 IRF3 IFNB1 IFIH1
30 alk-negative anaplastic large cell lymphoma 10.3 DPP4 ADA
31 tuberculous peritonitis 10.3 CEACAM5 ADA
32 pericardial tuberculosis 10.3 CEACAM5 ADA
33 hantavirus pulmonary syndrome 10.3 IRF3 IFNB1
34 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
35 pleural lipoma 10.3 CEACAM5 ADA
36 gastrointestinal tuberculosis 10.2 CEACAM5 ADA
37 pulmonary disease, chronic obstructive 10.2
38 chronic kidney disease 10.2
39 viral encephalitis 10.2 IFNB1 CXCL10 ADA
40 autoimmune disease 10.2
41 marburg hemorrhagic fever 10.2 SCARA3 FURIN
42 abdominal tuberculosis 10.2 CEACAM5 ADA
43 neutropenia 10.2
44 acute kidney failure 10.2
45 measles 10.2
46 microphthalmia with limb anomalies 10.2 ISG15 IRF3 IFNB1 IFIH1
47 primary bacterial infectious disease 10.2 IFNB1 CXCL10 ADA
48 croup 10.2 IFIH1 ACE2
49 systemic lupus erythematosus 10.2
50 glioblastoma multiforme 10.2
51 helix syndrome 10.1
52 thrombocytopenia 10.1
53 bronchiolitis 10.1
54 kidney disease 10.1
55 lymphopenia 10.1
56 end stage renal disease 10.1
57 lung disease 10.1
58 retinitis pigmentosa 10.1
59 neuroretinitis 10.1
60 retinitis 10.1
61 myeloid leukemia 10.1
62 lung cancer 10.1
63 leukemia, acute myeloid 10.1
64 thrombosis 10.1
65 hepatitis e 10.1 ISG15 IFNB1 ASZ1
66 common cold 10.0
67 disseminated intravascular coagulation 10.0
68 toxic shock syndrome 10.0
69 generalized anxiety disorder 10.0
70 post-traumatic stress disorder 10.0
71 congestive heart failure 10.0
72 acute stress disorder 10.0
73 47,xyy 10.0
74 colorectal cancer 10.0
75 proteasome-associated autoinflammatory syndrome 1 10.0
76 allergic hypersensitivity disease 10.0
77 liver cirrhosis 10.0
78 t-cell lymphoblastic leukemia/lymphoma 10.0
79 subacute delirium 10.0
80 lupus erythematosus 10.0
81 glioma 10.0
82 glial tumor 10.0
83 mycosis fungoides 10.0 DPP4 CXCL10 ADA
84 retinoblastoma 9.9
85 rheumatoid arthritis 9.9
86 small cell cancer of the lung 9.9
87 triiodothyronine receptor auxiliary protein 9.9
88 kawasaki disease 9.9
89 leukemia, acute lymphoblastic 3 9.9
90 melanoma, cutaneous malignant 10 9.9
91 mumps 9.9
92 brain cancer 9.9
93 melanoma 9.9
94 malignant glioma 9.9
95 familial retinoblastoma 9.9
96 severe combined immunodeficiency 9.9
97 retinal degeneration 9.9
98 fundus dystrophy 9.9
99 skin melanoma 9.9
100 leukemia, t-cell, chronic 9.9
101 mercury poisoning 9.9
102 inherited retinal disorder 9.9
103 precursor t-cell acute lymphoblastic leukemia 9.9
104 chilblain lupus 1 9.9 IRF3 IFIH1
105 hair whorl 9.9
106 myositis 9.9
107 otitis media 9.9
108 polykaryocytosis inducer 9.9
109 ocular motor apraxia 9.9
110 ataxia and polyneuropathy, adult-onset 9.9
111 west nile virus 9.9
112 fatty liver disease, nonalcoholic 1 9.9
113 dengue virus 9.9
114 peripheral vascular disease 9.9
115 cryptogenic organizing pneumonia 9.9
116 infective endocarditis 9.9
117 cardiac arrest 9.9
118 endocarditis 9.9
119 pertussis 9.9
120 rabies 9.9
121 adult respiratory distress syndrome 9.9
122 dengue disease 9.9
123 bronchopneumonia 9.9
124 acute kidney tubular necrosis 9.9
125 guillain-barre syndrome 9.9
126 rift valley fever 9.9
127 coccidioidomycosis 9.9
128 polyneuropathy 9.9
129 plasmodium falciparum malaria 9.9
130 critical illness polyneuropathy 9.9
131 disease of mental health 9.9
132 pneumothorax 9.9
133 vascular disease 9.9
134 pericarditis 9.9
135 thrombocytosis 9.9
136 bronchiolitis obliterans 9.9
137 pulmonary tuberculosis 9.9
138 ischemia 9.9
139 pulmonary fibrosis 9.9
140 acute myocarditis 9.9
141 poliomyelitis 9.9
142 bronchitis 9.9
143 hyperthyroidism 9.9
144 myocarditis 9.9
145 herpes simplex 9.9
146 diabetes insipidus 9.9
147 stomatitis 9.9
148 yellow fever 9.9
149 cytokine deficiency 9.9
150 acute sensory ataxic neuropathy 9.9
151 pik3ca-related overgrowth syndrome 9.9
152 cutaneous t cell lymphoma 9.9 DPP4 CXCL10 ADA
153 aicardi-goutieres syndrome 9.8 ISG15 IRF3 IFNB1 IFIH1 CXCL10 ADA
154 atherosclerosis susceptibility 9.8
155 breast cancer 9.8
156 hepatocellular carcinoma 9.8
157 glioma susceptibility 1 9.8
158 keratitis, hereditary 9.8
159 antigen defined by monoclonal antibody aj9 9.8
160 parkinson disease, late-onset 9.8
161 prostate cancer 9.8
162 suppressor of tumorigenicity 3 9.8
163 varicose veins 9.8
164 hemolytic uremic syndrome, atypical 1 9.8
165 myeloma, multiple 9.8
166 osteogenic sarcoma 9.8
167 kearns-sayre syndrome 9.8
168 autoimmune lymphoproliferative syndrome 9.8
169 macular degeneration, age-related, 1 9.8
170 alpha-thalassemia 9.8
171 myd88 deficiency 9.8
172 lung cancer susceptibility 3 9.8
173 hypotrichosis and recurrent skin vesicles 9.8
174 c1q deficiency 9.8
175 cyanosis, transient neonatal 9.8
176 graft-versus-host disease 9.8
177 interstitial nephritis, karyomegalic 9.8
178 pulmonary hypertension, primary, 3 9.8
179 pulmonary hypertension, primary, 4 9.8
180 speech and communication disorders 9.8
181 stargardt disease 9.8
182 bacterial sepsis 9.8
183 chikungunya 9.8
184 acute diarrhea 9.8
185 epidemic typhus 9.8
186 exanthem 9.8
187 small cell carcinoma 9.8
188 mantle cell lymphoma 9.8
189 limb ischemia 9.8
190 immunoglobulin alpha deficiency 9.8
191 aphasia 9.8
192 brain glioma 9.8
193 oral hairy leukoplakia 9.8
194 salmonellosis 9.8
195 childhood acute lymphocytic leukemia 9.8
196 thalassemia 9.8
197 pre-eclampsia 9.8
198 portal hypertension 9.8
199 sarcoma 9.8
200 esophageal varix 9.8
201 pulmonary edema 9.8
202 visual epilepsy 9.8
203 nephrotic syndrome 9.8
204 aseptic meningitis 9.8
205 leukemia 9.8
206 hemolytic-uremic syndrome 9.8
207 carotid stenosis 9.8
208 acute cystitis 9.8
209 scrub typhus 9.8
210 eclampsia 9.8
211 papilledema 9.8
212 cholera 9.8
213 histoplasmosis 9.8
214 viral hepatitis 9.8
215 enthesopathy 9.8
216 autoimmune hepatitis 9.8
217 transient cerebral ischemia 9.8
218 gastroenteritis 9.8
219 orchitis 9.8
220 hairy cell leukemia 9.8
221 cervix carcinoma 9.8
222 glomerulonephritis 9.8
223 astrocytoma 9.8
224 breast adenocarcinoma 9.8
225 plague 9.8
226 skin disease 9.8
227 liver disease 9.8
228 mutism 9.8
229 spindle cell sarcoma 9.8
230 rhinitis 9.8
231 movement disease 9.8
232 t-cell acute lymphoblastic leukemia 9.8
233 peripheral nervous system disease 9.8
234 eosinophilic pneumonia 9.8
235 acquired immunodeficiency syndrome 9.8
236 cerebrovascular disease 9.8
237 neuroblastoma 9.8
238 vasculitis 9.8
239 neuropathy 9.8
240 gas gangrene 9.8
241 lymphangitis 9.8
242 diabetes mellitus 9.8
243 bacterial meningitis 9.8
244 meningitis 9.8
245 pulmonary embolism 9.8
246 pulmonary eosinophilia 9.8
247 heart aneurysm 9.8
248 hypereosinophilic syndrome 9.8
249 48,xyyy 9.8
250 chronic graft versus host disease 9.8
251 dentinogenesis imperfecta type 2 9.8
252 haemophilus influenzae 9.8
253 hansen's disease 9.8
254 leukoplakia 9.8
255 splenomegaly 9.8
256 brain and spinal tumors 9.8
257 seizure disorder 9.8
258 tremor 9.8
259 systemic autoimmune disease 9.8
260 rapidly involuting congenital hemangioma 9.8
261 acute encephalopathy with biphasic seizures and late reduced diffusion 9.8
262 benign idiopathic neonatal seizures 9.8
263 methotrexate toxicity 9.8
264 postinfectious encephalitis 9.8
265 glomerular disease 9.8
266 thyroid carcinoma 9.8
267 noonan syndrome 6 9.8 PPP1CA IFIH1 ASZ1
268 viral infectious disease 9.7 ISG15 IRF3 IFNB1 IFIH1 CXCL10 ACE2
269 noonan syndrome 7 9.7 PPP1CA ASZ1

Graphical network of the top 20 diseases related to Middle East Respiratory Syndrome:



Diseases related to Middle East Respiratory Syndrome

Symptoms & Phenotypes for Middle East Respiratory Syndrome

MGI Mouse Phenotypes related to Middle East Respiratory Syndrome:

45 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.17 ACE2 ADA DPP4 HSPA5 IRF3 PRKRA

Drugs & Therapeutics for Middle East Respiratory Syndrome

Drugs for Middle East Respiratory Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 177, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
2
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
3 Adrenergic alpha-Agonists Phase 4
4 Adrenergic Agents Phase 4
5 Analgesics, Non-Narcotic Phase 4
6 Hypnotics and Sedatives Phase 4
7 Analgesics Phase 4
8 Adrenergic Agonists Phase 4
9 Neurotransmitter Agents Phase 4
10 Fibrinolytic Agents Phase 4
11 calcium heparin Phase 4
12 Anticoagulants Phase 4
13
tannic acid Approved Phase 2, Phase 3 1401-55-4
14
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
15
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
16
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
17
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
18 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
19
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
20
Colchicine Approved Phase 3 64-86-8 2833 6167
21
Lopinavir Approved Phase 3 192725-17-0 92727
22
Ritonavir Approved, Investigational Phase 3 155213-67-5 392622
23
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
24
Hydroxychloroquine Approved Phase 3 118-42-3 3652
25
Azithromycin Approved Phase 3 83905-01-5 447043 55185
26
Clarithromycin Approved Phase 3 81103-11-9 84029
27
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
28
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
29
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
30
Oseltamivir Approved Phase 3 204255-11-8, 196618-13-0 65028
31
Chlorpromazine Approved, Investigational, Vet_approved Phase 3 50-53-3 2726
32
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
33
Mannitol Approved, Investigational Phase 2, Phase 3 69-65-8 6251 453
34
chloroquine Approved, Investigational, Vet_approved Phase 2, Phase 3 54-05-7 2719
35
Zinc Approved, Investigational Phase 3 7440-66-6 32051
36
Ribavirin Approved Phase 3 36791-04-5 37542
37
Ivermectin Approved, Investigational, Vet_approved Phase 3 70288-86-7 6474909
38
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
39
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
40
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
41
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
42
Cobalamin Experimental Phase 3 13408-78-1 6857388
43
Nafamostat Investigational Phase 2, Phase 3 81525-10-2
44 Methylprednisolone Acetate Phase 2, Phase 3
45 glucocorticoids Phase 2, Phase 3
46 Neuroprotective Agents Phase 2, Phase 3
47 Immunologic Factors Phase 3
48 Immunoglobulins Phase 3
49 Antibodies Phase 3
50 Immunoglobulins, Intravenous Phase 3
51 Protein Kinase Inhibitors Phase 3
52 Tubulin Modulators Phase 3
53 Antimitotic Agents Phase 3
54 Anti-Infective Agents Phase 3
55 Antiviral Agents Phase 3
56
protease inhibitors Phase 2, Phase 3
57 HIV Protease Inhibitors Phase 2, Phase 3
58 Hormones Phase 3
59 Hormone Antagonists Phase 3
60 Antiemetics Phase 3
61 Protective Agents Phase 3
62 Gastrointestinal Agents Phase 3
63 Anti-Inflammatory Agents Phase 2, Phase 3
64 Antiparasitic Agents Phase 3
65 Serine Proteinase Inhibitors Phase 2, Phase 3
66 Sitagliptin Phosphate Phase 3
67 Antiprotozoal Agents Phase 3
68 Antimalarials Phase 3
69 Antirheumatic Agents Phase 3
70 Antioxidants Phase 3
71 silymarin Phase 3
72 Vitamin B 12 Phase 3
73 Dermatologic Agents Phase 3
74 Vitamin B12 Phase 3
75 Keratolytic Agents Phase 3
76 Anti-Bacterial Agents Phase 3
77 Antibiotics, Antitubercular Phase 2, Phase 3
78 Antipyretics Phase 2, Phase 3
79 Dopamine Antagonists Phase 3
80 Psychotropic Drugs Phase 3
81 Antipsychotic Agents Phase 3
82 Dopamine Agents Phase 3
83 Antimetabolites Phase 3
84 Complement System Proteins Phase 2, Phase 3
85 Immunosuppressive Agents Phase 2, Phase 3
86 Trypsin Inhibitors Phase 2, Phase 3
87 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
88 diuretics Phase 2, Phase 3
89 Chloroquine diphosphate Phase 2, Phase 3 50-63-5
90 Amebicides Phase 2, Phase 3
91 Insulin, Globin Zinc Phase 3
92 Dipeptidyl-Peptidase IV Inhibitors Phase 3
93 Hypoglycemic Agents Phase 3
94 insulin Phase 3
95 Incretins Phase 3
96 Zinc Supplement Phase 3
97 Epimedium Phase 2, Phase 3
98
Serine Investigational, Nutraceutical Phase 2, Phase 3 56-45-1 5951
99
Interferon beta-1b Approved Phase 2 145155-23-3
100
Enoxaparin Approved Phase 2 9005-49-6 772
101
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
102
Povidone-iodine Approved Phase 1, Phase 2 25655-41-8
103
Povidone Approved Phase 1, Phase 2 9003-39-8
104
Simvastatin Approved Phase 2 79902-63-9 54454
105
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
106
Nitric Oxide Approved Phase 2 10102-43-9 145068
107
Iron Approved, Experimental Phase 2 15438-31-0, 7439-89-6 27284 23925
108
Cetylpyridinium Approved Phase 2 7773-52-6
109
Hydrogen peroxide Approved, Vet_approved Phase 2 7722-84-1 784
110
Tamoxifen Approved Phase 2 10540-29-1 2733526
111
Decitabine Approved, Investigational Phase 1, Phase 2 2353-33-5 451668
112 Chlorine dioxide Investigational Phase 2 10049-04-4
113 Cytochrome P-450 Enzyme Inhibitors Phase 2
114 Interferon-beta Phase 2
115 Anti-HIV Agents Phase 2
116 Adjuvants, Immunologic Phase 2
117 Anti-Retroviral Agents Phase 2
118 Cytochrome P-450 CYP3A Inhibitors Phase 2
119 Convulsants Phase 2
120 Plasma Substitutes Phase 1, Phase 2
121 cadexomer iodine Phase 1, Phase 2
122 Blood Substitutes Phase 1, Phase 2
123 Hypolipidemic Agents Phase 2
124 Anticholesteremic Agents Phase 2
125 Lipid Regulating Agents Phase 2
126 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
127 Respiratory System Agents Phase 2
128 Vasodilator Agents Phase 2
129 Endothelium-Dependent Relaxing Factors Phase 2
130 Noni Phase 2
131 Anti-Asthmatic Agents Phase 2
132 Bronchodilator Agents Phase 2
133 Pharmaceutical Solutions Phase 2
134 Antineoplastic Agents, Hormonal Phase 2
135 Lactoferrin Phase 2
136 polysaccharide-K Phase 2
137 Antibodies, Blocking Phase 2
138 Anti-Infective Agents, Local Phase 2
139 Disinfectants Phase 2
140 Imatinib Mesylate Phase 2 220127-57-1 123596
141 Estrogens Phase 2
142 Estrogen Antagonists Phase 2
143 Estrogen Receptor Antagonists Phase 2
144 Estrogen Receptor Modulators Phase 2
145 Vaccines Phase 1, Phase 2
146 interferons Phase 1, Phase 2
147 Poly ICLC Phase 1, Phase 2
148
Sorbitol Approved Phase 1 50-70-4 5780
149
Glutamic acid Approved, Nutraceutical Phase 1 56-86-0 33032
150 Rho(D) Immune Globulin Phase 1
151 gamma-Globulins Phase 1
152 Myeloma Proteins Phase 1
153 Paraproteins Phase 1
154 Antibodies, Monoclonal Phase 1
155
Tinzaparin Approved 9041-08-1, 9005-49-6 25244225
156
Fondaparinux Approved, Investigational 104993-28-4
157
Dalteparin Approved 9005-49-6
158
Testosterone Approved, Experimental, Investigational 58-22-0, 481-30-1 10204 6013
159
Testosterone undecanoate Approved, Investigational 5949-44-0
160
Methyltestosterone Approved 58-18-4 6010
161
Testosterone enanthate Approved 315-37-7 9416
162 Rheumatoid Factor
163 Antithrombins
164 Antithrombin III
165 Factor Xa Inhibitors
166 Heparin, Low-Molecular-Weight
167 PENTA
168 Trace Elements
169 Nutrients
170 Micronutrients
171 Interferon-alpha Early Phase 1
172 Interferon alpha-2 Early Phase 1
173 Testosterone 17 beta-cypionate
174 Vitamins
175 Anabolic Agents
176 Androgens
177 Estrogens, Conjugated (USP)

Interventional clinical trials:

(showing 125, show less)
# Name Status NCT ID Phase Drugs
1 Effects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's Disease Unknown status NCT02982512 Phase 4 Dexmedetomidine
2 Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide Recruiting NCT04406246 Phase 4 Nitazoxanide 500Mg Oral Tablet
3 Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome Recruiting NCT04341493 Phase 4 Nitazoxanide 500 MG;Hydroxychloroquine
4 Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury Enrolling by invitation NCT04397510 Phase 4 Heparin;0.9% Sodium-chloride
5 MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial Completed NCT02845843 Phase 2, Phase 3 Combination of Lopinavir /Ritonavir and Interferon beta-1b;Placebo
6 Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial Completed NCT04244591 Phase 2, Phase 3 methylprednisolone therapy
7 Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh Recruiting NCT04402203 Phase 2, Phase 3 Favipiravir;Only Standard Treatment
8 Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19 Recruiting NCT04342182 Phase 2, Phase 3
9 Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19 Recruiting NCT04394416 Phase 3 Imatinib;Placebo oral tablet
10 The ECLA PHRI COLCOVID Trial Recruiting NCT04328480 Phase 3 Colchicine
11 Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection Recruiting NCT04385043 Phase 2, Phase 3 standard therapy
12 Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial Recruiting NCT04381858 Phase 3 Plasma from COVID-19 convalescent patient;Human immunoglobulin
13 Trial of Silymarin in Adults With COVID-19 Pneumonia Not yet recruiting NCT04394208 Phase 3 Silymarin;Placebo
14 Isotretinoin in Treatment of COVID-19 (Randomized) Not yet recruiting NCT04353180 Phase 3 Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment;Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment;Standard treatment
15 Repurposing of Chlorpromazine in Covid-19 Treatment Not yet recruiting NCT04366739 Phase 3 CHLORPROMAZINE (CPZ)
16 Effectiveness of Hydroxychloroquine in Covid-19 Patients: A Single Centred Single-blind RCT Study Not yet recruiting NCT04328272 Phase 3 Hydroxychloroquine 200 Mg Oral Tablet;Azithromycin 500Mg Oral Tablet
17 Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia Not yet recruiting NCT04380935 Phase 2, Phase 3 Standard of care
18 Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units. Not yet recruiting NCT04372979 Phase 3 Transfusion of SARS-CoV-2 Convalescent Plasma.;Transfusion of standard Plasma.
19 Treatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia: Open Labelled Randomized Controlled Clinical Trial Not yet recruiting NCT04418128 Phase 2, Phase 3 Nafamostat Mesylate
20 #StayHome: Efficacy of Early Hydroxychloroquine in Outpatients to Reduce Secondary Hospitalisation and Household Transmission of COVID-19 in Switzerland: A Double-blind, Randomised, Placebo-controlled Trial Not yet recruiting NCT04385264 Phase 2, Phase 3 Hydroxychloroquine;Mannitol
21 Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial Not yet recruiting NCT04333628 Phase 2, Phase 3 chloroquine
22 Study of the P2Et Extract Obtained From Caesalpinia Spinosa in the Symptomatic Treatment of Subjects With COVID-19 at the Hospital Universitario San Ignacio, Colombia. Not yet recruiting NCT04410510 Phase 2, Phase 3 P2Et (Caesalpinia spinosa extract)
23 The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients Not yet recruiting NCT04365517 Phase 3 Sitagliptin
24 Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: a Pilot Sequential Clinical Trial Not yet recruiting NCT04392427 Phase 3 Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
25 Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope Not yet recruiting NCT04361318 Phase 2, Phase 3
26 Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope Not yet recruiting NCT04360356 Phase 2, Phase 3
27 A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate COVID-19. Suspended NCT04252664 Phase 3 Remdesivir;Remdesivir placebo
28 Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19 Suspended NCT04278963 Phase 2, Phase 3 YinHu QingWen Decoction;YinHu QingWen Decoction(low dose)
29 An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19 Suspended NCT04310865 Phase 2, Phase 3 Yinhu Qingwen Granula;Yin Hu Qing Wen Granula(low does)
30 A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19. Terminated NCT04257656 Phase 3 Remdesivir;Remdesivir placebo
31 Phase I/IIa, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of GLS-5300, Administered ID Followed by CELLECTRA® 2000 (Electroporation, EP) Completed NCT03721718 Phase 1, Phase 2
32 Using Systems Vaccinology to Elucidate the Effects of Anti-inflammatory Therapy on Immune Response After Vaccination With a Live Attenuated Vaccine Completed NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
33 Double-blind, Placebo-controlled Study With an Open Dose Selection Period for Assessing the Safety and Immunogenicity of the Drug "BVRS-GamVac", a Vector Vaccine for the Prevention of the Middle East Respiratory Syndrome, Lyophilisate for the Preparation of a Solution for Intramuscular Administration, With the Participation of Healthy Volunteers Recruiting NCT04130594 Phase 1, Phase 2
34 Double-blind, Placebo-controlled Study With an Open Dose Selection Period for Assessing the Safety and Immunogenicity of the Drug "BVRS-GamVac-Combi", a Combined Vector Vaccine for the Prevention of the Middle East Respiratory Syndrome, Lyophilisate for the Preparation of a Solution for Intramuscular Administration, With the Participation of Healthy Volunteers Recruiting NCT04128059 Phase 1, Phase 2 BVRS-GamVac-Combi
35 A Phase 2, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19 Recruiting NCT04359810 Phase 2
36 A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 Cases Recruiting NCT04390503 Phase 2
37 A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 Recruiting NCT04347681 Phase 2
38 Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial Recruiting NCT04322773 Phase 2 RoActemra iv;RoActemra sc;Kevzara sc
39 Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial Recruiting NCT04405310 Phase 2
40 Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT Recruiting NCT04403477 Phase 2
41 Transfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2: a Multicenter Open Label Randomized Control Trial Recruiting NCT04393727 Phase 2
42 Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial Recruiting NCT04375098 Phase 2
43 Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers Recruiting NCT04347954 Phase 1, Phase 2 Povidone-Iodine 2%;Povidone-Iodine 0.5%;Isotonic saline 0.9%
44 An Open-label Randomized Controlled Trial on Interferon β-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection Recruiting NCT04350281 Phase 2 Interferon Beta-1B;Hydroxychloroquine
45 Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia Recruiting NCT04322565 Phase 2 Colchicine
46 Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial. Recruiting NCT04348695 Phase 2 Ruxolitinib plus simvastatin
47 A Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection Recruiting NCT04392232 Phase 2 Convalescent Plasma
48 A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-β1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection Recruiting NCT04385095 Phase 2 Interferon beta 1a;Placebo
49 Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic Recruiting NCT04364802 Phase 2 Povidone-Iodine Nasal Spray and Gargle;Povidone-Iodine Nasal Spray and Gargle
50 Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia Recruiting NCT04346147 Phase 2 Hidroxicloroquine;Lopinavir/ritonavir;Imatinib tablets;Baricitinib Oral Tablet
51 DETERMINATION OF THE DOSE AND EFFECTIVENESS OF CONVALESCENT PLASMA IN SEVERELY AND VERY SEVERELY ILL PATIENTS BY COVID-19 Recruiting NCT04356482 Phase 1, Phase 2
52 Hydroxychloroquine for Outpatients With Confirmed COVID-19 Recruiting NCT04342169 Phase 2 Hydroxychloroquine;Placebo oral tablet
53 Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19 Recruiting NCT04407182 Phase 2
54 Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab Recruiting NCT04363853 Phase 2 Tocilizumab
55 Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection Active, not recruiting NCT04337918 Phase 2 NORS (Nitric Oxide Releasing Solution);NORS (Nitric Oxide Releasing Solution)
56 Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory Therapy in Patients Diagnosed With COVID-19 Disease Not yet recruiting NCT04412395 Phase 2 Placebo of excipient(s) will be administered
57 Combination With Inhibitor of Neutrophil Elastase (All-trans Retinoic Acid ) and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated Vaccines Not yet recruiting NCT04396067 Phase 2 Aerosolized 13 cis retinoic acid;Aerosolized All trans retinoic acid
58 Effect of Antiseptic Mouthwash/Gargling Solutions and Pre-procedural Rinse on SARS-CoV-2 Load (COVID-19) Not yet recruiting NCT04409873 Phase 2 Oral-B Mouth Sore mouthwash;Crest Pro-Health Multi-Protection mouthwash;CloSYS mouthwash;Distilled water
59 A RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS. Not yet recruiting NCT04357613 Phase 2 Experimental drug
60 Inactivated Convalescent Plasma as a Therapeutic Alternative in Hospitalized Patients CoViD-19 Not yet recruiting NCT04385186 Phase 2 Inactivated convalescent plasma;Support treatment
61 Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus Not yet recruiting NCT04389580 Phase 2 Drug: Isotretinoin plus Tamoxifen;Aerosolized Isotretinoin plus Tamoxifen
62 A Phase I/Pilot II Trial Combining Decitabine and Vaccine Therapy for Patients With Relapsed or Refractory Pediatric High Grade Gliomas, Medulloblastomas, and Central Nervous System Primitive Neuroectodermal Tumors (CNS PNETs) Terminated NCT02332889 Phase 1, Phase 2 Decitabine and Hiltonol
63 Anti-MERS-COV Convalescent Plasma Therapy Withdrawn NCT02190799 Phase 2
64 Phase I, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5300, Administered IM Followed by Electroporation in Healthy Volunteers Completed NCT02670187 Phase 1
65 An Open, Single Center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S Completed NCT03615911 Phase 1
66 A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-301 in Healthy Adults Completed NCT02788188 Phase 1
67 Extracorporeal Membrane Oxygenation Support for Middle East Respiratory Syndrome Induced Respiratory Failure Completed NCT02627378 Phase 1
68 A Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 vs. Placebo in Healthy Adults Completed NCT03301090 Phase 1
69 A Phase Ib Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in Healthy Adult Middle Eastern Volunteers Recruiting NCT04170829 Phase 1
70 A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers Recruiting NCT03399578 Phase 1
71 Phase 1 First-in-Human, Time Lagged, Randomised, Placebo Controlled, Double Blind, Single Ascending Dose Study of TY027 in Healthy Adult Volunteers Recruiting NCT04429529 Phase 1
72 A Two-center, Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S_DF-1 in Healthy Study Subjects Not yet recruiting NCT04119440 Phase 1
73 A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Bacterial ACE2 Receptors -Like Enzyme 2 (rbACE2) and Isotretinoin Adult Patients With COVID-19 Not yet recruiting NCT04375046 Phase 1 Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)
74 Seroprevalence of IgG Antibodies to Middle East Respiratory Syndrome Coronavirus in Asymptomatic Healthcare Workers After Treatment of Confirmed MERS Patient Completed NCT02497885
75 Sitagliptin Treatment in Diabetic COVID-19 Positive Patients: Retrospective Study Completed NCT04382794 Retrospective case-control analysis
76 An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses Completed NCT01056354
77 Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV) and Infection Control Experiences in a Medical Institution of South Korea Completed NCT02605109
78 Prognostic Factors of Patients With COVID-19 Completed NCT04292964
79 The First in the World Human Proof-of-concept Study on Disinfection and Healing Acceleration Capabilities of 222nm Wave Length Narrow Band Ultraviolet Lighting Device Completed NCT03526068
80 Evaluation of the Evolution of Pregnancies in the First Trimester Following a Medically Assisted Procreation (MAR) Management During a COVD-19 Pandemic Period Recruiting NCT04415359
81 Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy Recruiting NCT04319016
82 Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy Recruiting NCT04315870
83 Seroprevalence of SARS-Cov-2 Antibodies in Children - a Prospective Multicentre Cohort Study Recruiting NCT04347408
84 European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID Patients in ECMO Recruiting NCT04366921
85 COPE - COVID-19 in Pregnancy and Early Childhood - a Study Protocol for a Prospective Multicentre Cohort Study Recruiting NCT04433364
86 Host-pathogen Interactions During Paediatric and Adult SARS-CoV-2 Infection (COVID-19) Recruiting NCT04376476
87 Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19 Recruiting NCT04413864
88 An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses Recruiting NCT01056185
89 Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19 Recruiting NCT04347538
90 Pilot Study on the Feasibility of Low Dose Radiotherapy for SARS-Cov-2 Pneumonitis (COVID-19 Low Dose Radiotherapy - COLOR 19) Recruiting NCT04377477
91 Genome-wide CRISPR Screen for Host Factors Associated With Norovirus Infections in Stem Cell-derived Human Intestinal Enteroid Model Recruiting NCT03342547
92 Exploring Brain Damages After COVID-19 Infection Recruiting NCT04405986
93 SARS-COV2 Pandemic Serosurvey and Blood Sampling Recruiting NCT04334954
94 Clinical Characterisation Protocol for Severe Emerging Infections Recruiting NCT04262921
95 Obstetric and Perinatal Outcomes of Women With COVID-19: A Prospective Cohort Study Recruiting NCT04369859
96 Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort Recruiting NCT04367805
97 Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety Recruiting NCT04397523
98 COVID-19 Imaging Features Recruiting NCT04394026
99 Characterization of Kidney Involvement in COVID-19 Disease: a French Multi-center Prospective Observational Study Recruiting NCT04355624
100 Collection of COVID-19 Convalescent Plasma Recruiting NCT04344015
101 Prospective Observational Study for Patients With HIV and Confirmed SARS-CoV-2 Recruiting NCT04333953
102 Retrospective Study From November 2019 -Febrauary 2020 on Severe Respiratory Illness to Access the Presence or Absence of COVID-19 in Patients Samples by Real-time PcR Recruiting NCT04346056
103 Prevalence and Clinical Characteristics of Novel COVID-19 Cases at One Quarantine Hospital; a National Analysis Recruiting NCT04413045
104 Clinical Characteristics and Outcomes of Children Potentially Infected by Severe Acute Respiratory Distress Syndrome (SARS)-CoV-2 Presenting to Pediatric Emergency Departments Recruiting NCT04330261
105 Covid Radiographic Images Data-set for A.I Recruiting NCT04419545
106 Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders: An Observational Study of the Covid-19 Neurological and Psychiatric Manifestations Recruiting NCT04362930
107 Genetic and Epigenetic Contribution to Increased Risk of T2D in the UAE Recruiting NCT04270097
108 A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIORII) Recruiting NCT04382391
109 Cardiopulmonary and Immunological Impacts of Covid-19 in a Cohort of Survivors Active, not recruiting NCT04388436
110 Impact of the Rheumatoid Factor on Serological Testing Performance for Covid-19 in Rheumatoid Arthritis Patients Active, not recruiting NCT04407559
111 Convalescent Plasma for the Treatment of Patients With COVID-19 Available NCT04372368
112 Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases Enrolling by invitation NCT02338986
113 Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia Not yet recruiting NCT04376840
114 National Prospective and Retrospective Follow-up of Patients With COVID-19 Infected Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenström Disease Not yet recruiting NCT04391946
115 Psychological Impact of COVID19 Among Doctors in Assiut University Hospitals Not yet recruiting NCT04363229
116 Increased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19) Not yet recruiting NCT04359212 thromboprophylaxis with low-molecular-weight heparin or fondaparinux
117 Prediction of Acute Kidney Injury in Patients With COVID-19 Associated Acute Respiratory Distress Syndrome Not yet recruiting NCT04406688
118 Investigation of the Effects of Exercise Using Telerehabilitation in Patients Diagnosed With Coronavirus (COVID-19) and Followed at Home Not yet recruiting NCT04346927
119 Various Molecular Markers With Predictive and Prognostic Significance in COVID-19 Outcome Not yet recruiting NCT04390269
120 Psychiatric Consultation for COVID-19 Patients Not yet recruiting NCT04395872
121 Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon α1β in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan Not yet recruiting NCT04293887 Early Phase 1 Recombinant human interferon α1β
122 In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity Not yet recruiting NCT04368897
123 Computed Tomography for Coronavirus Disease 19 Diagnosis Not yet recruiting NCT04355507
124 A Phase III Prospective, Interventional, Cohort, Superiority Study to Evaluate the Benefit of Rapid COVID-19 Genomic Sequencing (the COVID-19 GENOMICS UK Project) on Infection Control in Preventing the Spread of the Virus in United Kingdom NHS Hospitals Not yet recruiting NCT04405934
125 Incidence of Covid-19 in School Children During the Pandemic Period in Nice Withdrawn NCT04377737

Search NIH Clinical Center for Middle East Respiratory Syndrome

Genetic Tests for Middle East Respiratory Syndrome

Anatomical Context for Middle East Respiratory Syndrome

MalaCards organs/tissues related to Middle East Respiratory Syndrome:

40
T Cells, Testes, Brain, Lung, Kidney, B Cells, Subthalamic Nucleus

Publications for Middle East Respiratory Syndrome

Articles related to Middle East Respiratory Syndrome:

(showing 4965, show less)
# Title Authors PMID Year
1
Competing endogenous RNA network profiling reveals novel host dependency factors required for MERS-CoV propagation. 61
32223537 2020
2
COVID-19: animals, veterinary and zoonotic links. 61
32393111 2020
3
Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity. 61
32403995 2020
4
Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. 61
32196410 2020
5
Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. 61
32306853 2020
6
Inhibition of SARS-CoV 3CL protease by flavonoids. 61
31724441 2020
7
Emergency nurses' perceptions regarding the risks appraisal of the threat of the emerging infectious disease situation in emergency departments. 61
31975652 2020
8
Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. 61
32036774 2020
9
Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV. 61
32471334 2020
10
Animal models for emerging coronavirus: progress and new insights. 61
32378471 2020
11
COVID-19: Development of a robust mathematical model and simulation package with consideration for ageing population and time delay for control action and resusceptibility. 61
32536738 2020
12
Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. 61
32320825 2020
13
Structure and dynamics of phospholipids in membranes elucidated by combined use of NMR and vibrational spectroscopies. 61
32407775 2020
14
Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. 61
32360071 2020
15
Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review. 61
32450165 2020
16
Mathematical model of infection kinetics and its analysis for COVID-19, SARS and MERS. 61
32278147 2020
17
Possible environmental effects on the spread of COVID-19 in China. 61
32402910 2020
18
Coronaviruses pandemics: Can neutralizing antibodies help? 61
32450171 2020
19
Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 Mpro enzyme through in silico approach. 61
32450166 2020
20
What are the main patient safety concerns of healthcare stakeholders: a mixed-method study of Web-based text. 61
32416430 2020
21
Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus. 61
32203126 2020
22
Built-in RNA-mediated chaperone (chaperna) for antigen folding tailored to immunized hosts. 61
32297972 2020
23
Coronavirus in water environments: Occurrence, persistence and concentration methods - A scoping review. 61
32361598 2020
24
Natural product-derived phytochemicals as potential agents against coronaviruses: A review. 61
32360300 2020
25
Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. 61
32222463 2020
26
The diagnosis of pandemic coronavirus pneumonia: A review of radiology examination and laboratory test. 61
32438256 2020
27
The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century. 61
32322993 2020
28
Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. 61
32360583 2020
29
Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. 61
32361744 2020
30
[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. 61
32536988 2020
31
Reconfiguring the scope and practice of regional anesthesia in a pandemic: the COVID-19 perspective. 61
32471930 2020
32
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. 61
32227493 2020
33
Current epidemiological and clinical features of COVID-19; a global perspective from China. 61
32315723 2020
34
Assessment of the quality of systematic reviews on COVID-19: A comparative study of previous coronavirus outbreaks. 61
32301508 2020
35
The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients. 61
32320066 2020
36
Shell disorder analysis predicts greater resilience of the SARS-CoV-2 (COVID-19) outside the body and in body fluids. 61
32244041 2020
37
Sixty-eight consecutive patients assessed for COVID-19 infection: Experience from a UK Regional infectious diseases Unit. 61
32223012 2020
38
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? 61
32291137 2020
39
Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. 61
32506195 2020
40
Epidemiological analysis of COVID-19 and practical experience from China. 61
32237160 2020
41
Clinical Insights into the Gastrointestinal Manifestations of COVID-19. 61
32447742 2020
42
COVID-19, SARS and MERS: A neurological perspective. 61
32417124 2020
43
COVID-19: A promising cure for the global panic. 61
32278175 2020
44
COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. 61
32257431 2020
45
Myocardial injury and COVID-19: Possible mechanisms. 61
32360126 2020
46
Current targeted therapeutics against COVID-19: Based on first-line experience in China. 61
32360585 2020
47
Advances in the relationship between coronavirus infection and cardiovascular diseases. 61
32428835 2020
48
The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. 61
32283144 2020
49
The Role of Human Coronavirus Infection in Pediatric Acute Gastroenteritis. 61
32433226 2020
50
Surveillance and Testing for Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, March 2016-March 2019. 61
32568049 2020
51
Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. 61
32437679 2020
52
Assessing the Presence of Post-Traumatic Stress and Turnover Intention Among Nurses Post-Middle East Respiratory Syndrome Outbreak: The Importance of Supervisor Support. 61
32146875 2020
53
What can psychiatrists learn from SARS and MERS outbreaks? 61
32437680 2020
54
Overview: The history and pediatric perspectives of severe acute respiratory syndromes: Novel or just like SARS. 61
32483934 2020
55
Mysterious Virus: A Review on Behavior and Treatment Approaches of the Novel Coronavirus, 2019-nCoV. 61
32448490 2020
56
Comparison of commercial realtime reverse transcription PCR assays for the detection of SARS-CoV-2. 61
32570045 2020
57
Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics. 61
32574109 2020
58
Multimeric conformation of type III intermediate filaments but not the filamentous conformation exhibits high affinity to lipid bilayers. 61
32243065 2020
59
[Remdesivir, the antiviral hope against SARS-CoV-2]. 61
32239125 2020
60
Human Gene Sequences in SARS-CoV-2 and Other Viruses. 61
32503822 2020
61
Cold and distant: structural features of the nucleoprotein complex of a cold-adapted influenza A virus strain. 61
32490728 2020
62
Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. 61
32518317 2020
63
Cranial Neuropathies and COVID-19: Neurotropism and Autoimmunity. 61
32487714 2020
64
Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial. 61
32513231 2020
65
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. 61
32507409 2020
66
ITP flare with mild COVID-19 infection in pregnancy: A case report. 61
32516503 2020
67
COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection. 61
32575380 2020
68
A Putative Role of de-Mono-ADP-Ribosylation of STAT1 by the SARS-CoV-2 Nsp3 Protein in the Cytokine Storm Syndrome of COVID-19. 61
32549200 2020
69
SARS-CoV-2: Is it the newest spark in the TORCH? 61
32335336 2020
70
Spatial association between primary Middle East respiratory syndrome coronavirus infection and exposure to dromedary camels in Saudi Arabia. 61
32112508 2020
71
Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action. 61
32350686 2020
72
COVID-19 and Other Pandemics: How Might They Be Prevented? 61
32478500 2020
73
[SARS-CoV-2 infection (COVID-19): what can we expect?] 61
32492743 2020
74
COVID-19, SARS and MERS: are they closely related? 61
32234451 2020
75
The possible of immunotherapy for COVID-19: A systematic review. 61
32272396 2020
76
COVID-19 and pregnancy: a review of current knowledge. 61
32532938 2020
77
Recommendations for Dental Care during COVID-19 Pandemic. 61
32545477 2020
78
Impact of coronavirus (COVID-19) on otolaryngologic surgery: Brief commentary. 61
32270565 2020
79
The trinity of COVID-19: immunity, inflammation and intervention. 61
32346093 2020
80
Association of COVID-19 pandemic with meteorological parameters over Singapore. 61
32544735 2020
81
Neurological manifestations of COVID-19, SARS and MERS. 61
32562214 2020
82
Type 1 interferons as a potential treatment against COVID-19. 61
32275914 2020
83
Autophagy/virophagy: a "disposal strategy" to combat COVID-19. 61
32578486 2020
84
COVID-19: laboratory diagnosis for clinicians. An updating article. 61
32578747 2020
85
COVID-19 vaccine development and the way forward. 61
32496238 2020
86
Repurposing chlorpromazine to treat COVID-19: The reCoVery study. 61
32425222 2020
87
Effect of COVID-19 on liver transplantation in KOREA. 61
32574408 2020
88
COVID-19 Outbreak in Malaysia. 61
32494567 2020
89
COVID-19 and the clinical hematology laboratory. 61
32311826 2020
90
Rationale for targeting Complement in COVID-19. 61
32559343 2020
91
COVID-19: Time for Post-Exposure Prophylaxis? 61
32512873 2020
92
Cardiovascular Implications in Patients Infected with Covid-19 and the Importance of Social Isolation to Reduce Dissemination of the Disease. 61
32491075 2020
93
Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). 61
32369402 2020
94
Learning from the past: did experience with previous epidemics help mitigate the impact of COVID-19 among spine surgeons worldwide? 61
32500177 2020
95
The Role of Health Technology and Informatics in Global Public Health Emergency: Practices and Implications from the COVID-19 Pandemic. 61
32568725 2020
96
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. 61
32526193 2020
97
COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs. 61
32532764 2020
98
Are dental schools adequately preparing dental students to face outbreaks of infectious diseases such as COVID-19? 61
32391578 2020
99
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. 61
32562601 2020
100
The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. 61
32446778 2020
101
Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. 61
32305883 2020
102
The psychological impact of COVID-19 pandemic on health care workers in a MERS-CoV endemic country. 61
32505461 2020
103
An evidence-based framework for priority clinical research questions for COVID-19. 61
32257173 2020
104
Hemodialysis with Cohort Isolation to Prevent Secondary Transmission during a COVID-19 Outbreak in Korea. 61
32482688 2020
105
COVID-19: is there a link between the course of infection and pharmacological agents in diabetes? 61
32495299 2020
106
SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review. 61
32429703 2020
107
Management of used personal protective equipment and wastes related to COVID-19 in South Korea. 61
32517547 2020
108
Deployment of convalescent plasma for the prevention and treatment of COVID-19. 61
32254064 2020
109
ECMO use in COVID-19: lessons from past respiratory virus outbreaks-a narrative review. 61
32505217 2020
110
Prior and novel coronaviruses, Coronavirus Disease 2019 (COVID-19), and human reproduction: what is known? 61
32482250 2020
111
Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study. 61
32315171 2020
112
COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. 61
32522207 2020
113
The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. 61
32104915 2020
114
Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. 61
32134116 2020
115
Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. 61
32315817 2020
116
South Korea's Reponses to Stop the COVID-19 Pandemic. 61
32522606 2020
117
Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic. 61
32574894 2020
118
Opportunities and Challenges for Biosensors and Nanoscale Analytical Tools for Pandemics: COVID-19. 61
32551559 2020
119
Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective. 61
32506725 2020
120
Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring. 61
32524645 2020
121
Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. 61
32535232 2020
122
The broad-spectrum antiviral recommendations for drug discovery against COVID-19. 61
32546018 2020
123
Super-spreading events and contribution to transmission of MERS, SARS, and SARS-CoV-2 (COVID-19). 61
32277963 2020
124
CLINICAL CHARACTERISTICS OF 28 PATIENTS WITH DIABETES AND COVID-19 IN WUHAN, CHINA. 61
32357072 2020
125
Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). 61
32563999 2020
126
Cytokine storm intervention in the early stages of COVID-19 pneumonia. 61
32360420 2020
127
Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations. 61
32396137 2020
128
Preparedness and response to COVID-19 in Saudi Arabia: Building on MERS experience. 61
32451260 2020
129
SARS, MERS and COVID-19 among healthcare workers: A narrative review. 61
32493671 2020
130
B-cell engineering: A promising approach towards vaccine development for COVID-19. 61
32516733 2020
131
SARS-CoV, Mers-CoV and Covid-19:what differences from a dermatological viewpoint? 61
32526085 2020
132
Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19. 61
32532933 2020
133
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. 61
32534189 2020
134
Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics. 61
32324951 2020
135
Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. 61
32464097 2020
136
Neurological and Psychological Effects of Coronavirus (COVID-19): An Overview of the Current Era Pandemic. 61